event result
action rais target price nippon shinyaku
potenti return maintain outperform rate
rais sale forecast cut op due higher sg spend
compani ramp us busi also introduc
invest overview anticip greater oversea sale growth
uptravi due increas market effort johnson johnson
forecast nippon shinyaku receiv commerci mileston worth
result us phase japan phase studi compani
key pipelin asset duchenn muscular dystrophi slate
new direct biolog diseas skelet muscl confer
june result favor anticip greater interest
compani oligonucleotide-bas technolog posit share price
reaction asset assum next trial
myelofibrosi start within fiscal year depend file
competitor fedratinib nippon shinyaku also schedul launch
obinutuzumab diffus larg b-cell lymphoma chugai year
catalysts/risk expect file us japan within
fiscal year result posit demonstr increas dystrophin
express addit celgen schedul file fedratinib approv
within year view delay due safeti concern request
addit trial posit nippon shinyaku downsid risk includ
oversea sale uptravi trend market expect
valuat expect launch base
target price ep recent forward
price-to-earnings bloomberg estim previous use ep
averag forward price-to-earnings last year
opt use higher multipl reflect rise expect
valuat metric
chang tp
number share mn
price month
price rel chart measur perform
topix close
spot exchang rate
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
price jun upsid rate outperform target price analyst yen ting chen
profit tax
issuanc retir stock
net chang cash
number share mn
urinari disord caus bph
cancer chronic pain
dev
file
dev
royalti licens
urinari disord caus bph
cancer chronic pain
dev
file
dev
royalti licens
figur profit loss statement
profit tax
number share million
chang work capit
chang debt
chang equiti
chang equival
cash equival
valuat translat adjust
subscript right share
liabil equiti
compani mention price
